India wants to be the “pharmacy of the world” \u2014 a $250 billion pharmaceutical export powerhouse supplying affordable generics to every corner of the globe. But a single structural problem stands in the way: the country’s drug regulator doesn’t have enough people to do the job.<\/p>\n\n\n\n
As Business Standard<\/strong> reported on August 20, 2026, India’s pharmaceutical ambitions are increasingly running into a regulatory capacity constraint. The Central Drugs Standard Control Organization (CDSCO) \u2014 the national authority responsible for approving new drugs, monitoring manufacturing quality, and ensuring import\/export compliance \u2014 is operating with a significant shortfall in technical staff, inspectors, and regulatory expertise.<\/p>\n\n\n\n This is not a new problem, but it is intensifying. India’s generic drug manufacturing sector has grown dramatically in scale and complexity: the country now produces over 20% of the world’s generic medicines by volume, and its exports span dozens of regulated markets including the United States, the European Union, the United Kingdom, and Australia. Each of these markets requires a different level of regulatory oversight, documentation, and inspection readiness \u2014 all of which ultimately flow through CDSCO’s domestic capacity.<\/p>\n\n\n\n CDSCO’s mandate covers several critical functions that directly affect the quality and safety of Indian generic medicines shipped worldwide:<\/p>\n\n\n\n When any of these functions is understaffed, the entire quality assurance chain weakens. Approvals slow down. Inspections get deferred. Import-export documentation gaps go longer without correction. And for international buyers \u2014 hospitals, pharmacies, and procurement agencies sourcing Indian generics \u2014 the risk of receiving a product that has not undergone adequate domestic regulatory scrutiny increases.<\/p>\n\n\n\n The regulatory capacity problem has not gone unnoticed. On August 3, 2026, Drug Controller General of India (DCGI) Dr. Rajesh Kumar Raghuvanshi announced that CDSCO would launch the first phase of an end-to-end digital drug regulatory platform within 18 months, as covered by Pharmabiz<\/strong>, The Hindu BusinessLine<\/strong> (August 8), Medical Dialogues<\/strong>, Express Pharma<\/strong>, and The Economic Times<\/strong>.<\/p>\n\n\n\n The platform is intended to consolidate the multiple portals, workflows, and data systems that currently fragment India’s drug regulatory process \u2014 addressing delays, glitches, and inconsistencies that industry stakeholders have complained about for years. A unified digital system could theoretically speed up approvals, centralize inspection records, and make regulatory compliance more transparent for manufacturers and buyers alike.<\/p>\n\n\n\n But a software platform does not replace inspectors. Digital workflows can reduce administrative friction, but the physical act of verifying a manufacturing site, sampling a drug batch, reviewing a quality dossier, or investigating a field complaint still requires trained human beings. The digital platform is a modernization step \u2014 it is not a substitute for regulatory capacity.<\/p>\n\n\n\n The Business Standard analysis highlights a deeper structural issue: India’s regulatory ambition has outpaced its regulatory workforce. Training pharmaceutical inspectors, regulatory affairs officers, and quality assurance evaluators takes years \u2014 and the pipeline of qualified personnel has not kept pace with the sector’s growth.<\/p>\n\n\n\n This is not unique to India. Regulatory agencies worldwide face similar capacity challenges \u2014 the U.S. FDA, the European Medicines Agency (EMA), and national regulators in importing countries all struggle with staffing constraints relative to the volume of products they oversee. But India’s position as a high-volume, low-cost generic manufacturer makes the stakes particularly high: when CDSCO’s capacity is stretched, the products most likely to slip through are the high-volume, lower-margin generics that form the backbone of India’s export economy.<\/p>\n\n\n\n For international buyers \u2014 whether hospitals in Africa, pharmacies in the Middle East, or procurement agencies in Southeast Asia \u2014 the CDSCO capacity constraint is a signal to be more diligent, not less confident. Indian generic medicines remain an essential source of affordable treatment globally, and the vast majority are manufactured to high standards. But the regulatory environment is evolving, and due diligence matters more than ever.<\/p>\n\n\n\n India’s pharmaceutical sector stands at a crossroads. The $250 billion export vision is not unrealistic \u2014 the industry has the manufacturing capacity, the cost advantage, and the global demand to make it achievable. But regulatory credibility is the currency that buys access to the world’s most profitable pharmaceutical markets, and CDSCO’s capacity is the foundation of that credibility.<\/p>\n\n\n\n The digital platform announcement is a welcome step toward modernizing India’s drug regulatory infrastructure. The staffing and expertise gap is a harder problem \u2014 it requires investment in training programs, recruitment, and retention of qualified regulatory professionals. Both are necessary. Neither alone is sufficient.<\/p>\n\n\n\n Sources: Business Standard (August 20, 2026); Pharmabiz (August 3, 2026); The Hindu BusinessLine (August 8, 2026); Medical Dialogues (July 31, 2026); Express Pharma (July 31, 2026).<\/em><\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n","protected":false},"excerpt":{"rendered":" India wants to be the “pharmacy of the world” \u2014 a $250 billion pharmaceutical export powerhouse supplying affordable generics to every corner of the globe. But a single structural problem stands in the way: the country’s drug regulator doesn’t have enough people to do the job. The Regulatory Capacity Constraint As Business Standard reported on […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[42,48,29,49],"class_list":["post-3672","post","type-post","status-publish","format-standard","hentry","category-news","tag-cdsco","tag-generic-medicines","tag-india-pharmacy","tag-indian-pharma","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3672"}],"version-history":[{"count":0,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3672\/revisions"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What CDSCO Does \u2014 and Why the Gap Matters<\/h2>\n\n\n\n
\n
The Digital Platform: A Partial Fix<\/h2>\n\n\n\n
The Human Capital Gap<\/h2>\n\n\n\n
What This Means for Buyers of Indian Generic Medicines<\/h2>\n\n\n\n
\n
The Bigger Picture<\/h2>\n\n\n\n